全球制药赢家——专注和效率为致胜秘笈_18页_2mb

Global Pharmaceutical Winners Summary

The global pharmaceutical industry, as analyzed in the 2023 Roland Berger report, consistently outperforms major stock markets due to efficiency gains in cost reduction and innovation. Top-performing companies, identified through examining over 150 leading firms from 2019 to 2022, share four key characteristics: business leadership, strategic consistency, proven execution ability, and appropriate scale along with strong financial health. Business leaders achieve high revenue growth, often through specialization; strategic focus enables portfolio synergies and ESG leadership; execution excellence is shown in operational efficiencies, such as lower SG&A and COGS expenses; scale and finances involve larger size and better capital access. Winners are prevalent in sectors like blood plasma treatments, contract development and manufacturing organizations (CDMOs), and traditional biotech, while underperformers lag in growth and profitability. Key recommendations for all companies include prioritizing these winning factors to enhance shareholder returns and navigate challenges like pricing pressures and innovation costs.

Key Highlights

• Industry Performance: Pharmaceutical industry TSR outpaces other sectors, with winners showing 22% average annual return.
• Winning Factors: Four distinct traits differentiate winners:
  • Business leadership: High revenue growth and market focus.
  • Strategic consistency: Clear value propositions and consistent investments.
  • Proven execution: Efficient resource deployment and cost control.
  • Scale and financial health: Larger size and robust capital structure for sustained growth.
• Sub-segment Insights: Blood plasma, CMO/CDMO, and traditional biotech sectors have the highest winner share, with challenges varying by area.
• Implications: Executives should use the assessment grid to evaluate their company's performance and address gaps to achieve superior returns.